Foreign Exchange Risk Associated with Growth in Overseas Sales
First written in FY2016. 6 of 33 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2026.
Sysmex moved to the "Worse" side of this theme in 2016, the same year as the typical company in this theme.
The whole theme swung hardest in 2019: 29 of 63 companies on the "Worse" side.
22 other companies' latest entry also says "Other".
- FY2026Updated full-year foreign exchange exposure and sensitivityAnnual report
「Overseas sales as a percentage of consolidated sales remained high at 86.7% in the fiscal year ended March 2025 and 88.3% in the fiscal year ending March 2026. The impact of a ¥1 change in exchange rates on sales and operating income in the fiscal year ending March 2026 is ¥798 million in sales and ¥207 million in operating income for USD, ¥596 million in sales and ¥71 million in operating income for EUR, and ¥4,089 million in sales and ¥2,993 million in operating income for CNY.」
The overseas sales ratio rose to 88.3%. Updated the sensitivity of sales and operating income to a ¥1 change in the USD, EUR and CNY exchange rates. - FY2026-H1Updated the first-half foreign exchange impact and overseas exposureAnnual report
「Overseas sales declined due to lower sales of hematology instruments, reagents and maintenance services, as well as coagulation and urinalysis reagents, while the yen strengthened against foreign currencies. As a result, overseas sales amounted to ¥207,092 million, down 2.4% year on year, and accounted for 89.1% of total sales, up 1.6 percentage points year on year. Foreign exchange gain or loss (△ indicates a loss) △689」
The overseas sales ratio rose to 89.1%, while the stronger yen contributed to the decline in overseas sales. The foreign exchange loss was ¥689 million, down from a loss of ¥4,030 million in the same period of the previous year. - FY2025-H1Updated overseas exposure and foreign exchange effects for the first halfAnnual report
「Overseas sales increased due to higher sales of hematology reagents and maintenance services, as well as coagulation and urinalysis reagents, while the yen remained weak against foreign currencies. As a result, overseas sales amounted to ¥212,156 million, up 14.7% year on year, and accounted for 87.5% of total sales, up 0.5 percentage points year on year.」
The overseas sales ratio rose to 87.5%, with the weaker yen contributing to the increase in overseas sales. Meanwhile, the first-half foreign exchange gain or loss was a loss of ¥4,030 million, indicating that currency movements affected earnings. - FY2024Updated full-year overseas exposure and foreign exchange sensitivityAnnual report
「Overseas sales have remained high as a percentage of consolidated sales, at 85.4% in the fiscal year ended March 2023 and 86.5% in the fiscal year ended March 2024. Because each line item in the financial statements of overseas affiliates denominated in local currencies is affected by exchange-rate fluctuations when translated into yen, such fluctuations affect the Group's operating results and financial position.」
The overseas sales ratio rose to 86.5%. The Company disclosed the impact of a ¥1 fluctuation as follows: USD, ¥735 million on sales and ¥127 million on operating profit; EUR, ¥511 million and ¥91 million; and CNY, ¥5,330 million and ¥3,888 million, respectively. - FY2024-Q3Updated overseas exposure and foreign exchange effects for the nine months ended Q3Annual report
「In overseas sales, sales of equipment, reagents and maintenance services in the hematology field increased. In addition, the yen remained weak against other currencies. As a result, overseas sales totaled ¥283,210 million, up 11.1% year on year, accounting for 86.7% of sales, up 1.3 percentage points year on year.」
The overseas sales ratio rose to 86.7%, and the weaker yen was a factor behind higher overseas sales. Foreign exchange gains and losses for the nine months ended Q3 showed a gain of ¥190 million. - FY2024-Q2Updated overseas exposure and foreign exchange effects for the six months ended Q2Annual report
「Overseas sales totaled ¥185,030 million, up 12.0% year on year, accounting for 87.0% of sales, up 1.9 percentage points year on year.」
The overseas sales ratio rose to 87.0%, and the weaker yen was a factor behind higher overseas sales. Foreign exchange gains and losses for the six months ended Q2 showed a gain of ¥1,351 million. - FY2024-Q1Updated first-quarter foreign exchange effects and overseas exposureAnnual report
「In overseas sales, sales of reagents and maintenance services in the hematology field and reagents in the urinalysis field increased. In addition, the yen remained weak against other currencies. As a result, overseas sales totaled ¥82,315 million, up 12.7% year on year, accounting for 86.3% of sales, up 1.4 percentage points year on year.」
The overseas sales ratio rose to 86.3%, and the weaker yen was a factor behind higher overseas sales. Foreign exchange gains and losses for the first quarter showed a gain of ¥856 million, with the impact of foreign exchange fluctuations appearing in actual results. - FY2023Updated full-year foreign exchange exposure and sensitivityAnnual report
「Overseas sales have remained high as a percentage of consolidated sales, at 84.7% in the fiscal year ended March 2022 and 85.4% in the fiscal year ended March 2023. Each line item in the financial statements of overseas affiliates denominated in local currencies is affected by changes in exchange rates when translated into yen.」
The overseas sales ratio rose to 85.4%. The Company disclosed the impact of a ¥1 fluctuation as follows: USD, ¥703 million on sales and ¥150 million on operating profit; EUR, ¥534 million and ¥128 million; and CNY, ¥4,828 million and ¥3,681 million, respectively. - FY2023-Q3Updated foreign exchange effects for the nine months ended Q3Annual report
「Foreign exchange gains and losses (△ indicates a loss) △773」
Foreign exchange gains and losses for the nine months ended Q3 showed a loss of ¥773 million, compared with a gain of ¥442 million in the same period of the previous year. The overseas sales ratio remained high at 85.4%, and the weaker yen was cited as a factor behind higher overseas sales. - FY2023-Q2Updated foreign exchange effects and overseas exposure for the six months ended Q2Annual report
「In overseas sales, although the same period of the previous year was affected by the spread of COVID-19, reagent sales increased mainly in the hematology, urinalysis and blood coagulation testing fields as testing demand recovered. In addition, the yen remained weak against other currencies. As a result, the Group's overseas sales totaled ¥165,229 million, up 15.4% year on year, accounting for 85.1% of sales, up 0.1 percentage points year on year.」
The overseas sales ratio remained high at 85.1%, and the weaker yen was a factor behind higher overseas sales. Foreign exchange gains and losses for the six months ended Q2 showed a gain of ¥3,185 million. - FY2023-Q1Updated first-quarter foreign exchange gains and lossesAnnual report
「Foreign exchange gains and losses (△ indicates a loss) 2,931」
Foreign exchange gains and losses for the six months ended Q1 showed a gain of ¥2,931 million, up from a gain of ¥250 million in the same period of the previous year. - FY2022Updated full-year foreign exchange exposure and sensitivityAnnual report
「The Group sells overseas through overseas affiliates and distributors. Overseas sales have remained high as a percentage of consolidated sales, at 84.0% in the fiscal year ended March 2021 and 84.7% in the fiscal year ended March 2022. Each line item in the financial statements of overseas affiliates denominated in local currencies is affected by changes in exchange rates when translated into yen.」
The overseas sales ratio rose to 84.7%. The Company disclosed the impact of a ¥1 fluctuation as follows: USD, ¥688 million on sales and ¥166 million on operating profit; EUR, ¥534 million and ¥153 million; and CNY, ¥5,246 million and ¥3,921 million, respectively. Foreign exchange gains and losses for the fiscal year showed a gain of ¥850 million. - FY2022-Q3Updated foreign exchange gains and losses for the nine months ended Q3Annual report
「Foreign exchange gains and losses (△ indicates a loss) 442」
Foreign exchange gains and losses for the nine months ended Q3 showed a gain of ¥442 million. The overseas sales ratio remained high at 84.9%. The impact of foreign exchange risk appeared in earnings. - FY2022-Q2Updated foreign exchange gains and losses for the six months ended Q2Annual report
「Foreign exchange gains and losses (△ indicates a loss) △19」
Foreign exchange gains and losses for the six months ended Q2 showed a loss of ¥19 million. - FY2022-Q1Updated first-quarter foreign exchange gains and lossesAnnual report
「Foreign exchange gains and losses (△ indicates a loss) 250」
Foreign exchange gains and losses for the six months ended Q1 showed a gain of ¥250 million, compared with a gain of ¥90 million in the same period of the previous year. - FY2021Updated full-year foreign exchange exposure and sensitivityAnnual report
「Overseas sales have remained high as a percentage of consolidated sales, at 84.5% in the fiscal year ended March 2020 and 84.0% in the fiscal year ended March 2021. Each line item in the financial statements of overseas affiliates denominated in local currencies is affected by changes in exchange rates when translated into yen.」
The overseas sales ratio declined to 84.0% but remained high. The Company disclosed the impact of a ¥1 fluctuation as follows: USD, ¥586 million on sales and ¥126 million on operating profit; EUR, ¥483 million and ¥146 million; and CNY, ¥5,250 million and ¥3,954 million, respectively. - FY2021-Q3Updated foreign exchange gains and losses for the nine months ended Q3Annual report
「Foreign exchange gains and losses (△ indicates a loss) △648」
Foreign exchange gains and losses for the nine months ended Q3 showed a loss of ¥648 million. - FY2021-Q2Updated foreign exchange gains and losses for the six months ended Q2Annual report
「Foreign exchange gains and losses (△ indicates a loss) △701」
Foreign exchange gains and losses for the six months ended Q2 showed a loss of ¥701 million. - FY2021-Q1Updated first-quarter foreign exchange gains and lossesAnnual report
「Foreign exchange gains and losses (△ indicates a loss) 90」
Foreign exchange gains and losses for the six months ended Q1 showed a gain of ¥90 million, compared with a loss of ¥1,065 million in the same period of the previous year. - FY2020WorsenedAnnual report
「Overseas sales have remained high as a percentage of consolidated sales, at 85.0% in the fiscal year ended March 2019 and 84.5% in the fiscal year ended March 2020. The Company addresses this through measures including risk hedging with forward foreign exchange contracts, but the operating results and financial position of the Group are affected by foreign exchange fluctuations. The impact of foreign exchange fluctuations in the fiscal year ended March 2020 was as follows.」
In addition to an overseas sales ratio of 84.5%, the Company disclosed the impact on sales and operating profit of a ¥1 fluctuation by currency. Foreign exchange effects reduced profit by ¥5,289 million year on year, while foreign exchange losses increased to ¥3,017 million. - FY2020-Q3Updated foreign exchange gains and losses for the nine months ended Q3Annual report
「Foreign exchange gains and losses (△ indicates a loss) △1,442」
Foreign exchange gains and losses for the nine months ended Q3 showed a loss of ¥1,442 million. - FY2020-Q2Updated foreign exchange gains and losses for the six months ended Q2Annual report
「Foreign exchange gains and losses (△ indicates a loss) △1,671」
Foreign exchange gains and losses for the six months ended Q2 showed a loss of ¥1,671 million. - FY2020-Q1Updated first-quarter foreign exchange gains and lossesAnnual report
「Foreign exchange gains and losses (△ indicates a loss) △1,065」
Foreign exchange gains and losses for the six months ended Q1 showed a loss of ¥1,065 million. - FY2019-Q3Updated foreign exchange gains and losses for the nine months ended Q3Annual report
「Foreign exchange gains and losses (△ indicates a loss) △1,460」
Foreign exchange gains and losses for the nine months ended Q3 showed a loss of ¥1,460 million. - FY2019-Q2Updated foreign exchange gains and losses for the six months ended Q2Annual report
「Foreign exchange gains and losses (△ indicates a loss) △1,313」
Foreign exchange gains and losses for the six months ended Q2 showed a loss of ¥1,313 million. - FY2019-Q1MaterialisedAnnual report
「Profit at the segment level, or operating profit, was ¥8,097 million, down 14.1% year on year, due to lower intergroup export sales and deterioration in export profitability resulting from foreign exchange effects.」
Deterioration in export profitability due to foreign exchange effects appeared as a factor behind lower profit in the Japan segment. Foreign exchange gains and losses for the first quarter also showed a loss of ¥586 million. - FY2018MaterialisedAnnual report
「Overseas sales have remained high as a percentage of consolidated sales, at 82.6% in the fiscal year ended March 2017 and 84.0% in the fiscal year ended March 2018. The Company implements risk hedging through forward foreign exchange contracts and other measures, but the operating results and financial position of the Group are affected by foreign exchange fluctuations. Profit before income taxes increased by ¥9,170 million, or 18.7%, year on year to ¥58,117 million, mainly due to higher operating profit, a ¥1,221 million gain on the sale of shares in an affiliate, and a ¥946 million, or 42.7%, year-on-year decrease in foreign exchange losses to ¥1,272 million.」
As the overseas sales ratio rose to 84.0%, a foreign exchange loss of ¥1,272 million was recognized in full-year earnings, showing the impact of foreign exchange fluctuations in actual results. - FY2018-Q3Updated foreign exchange gains and losses for the nine months ended Q3Annual report
「Foreign exchange gains and losses (△ indicates a loss) △315」
Foreign exchange gains and losses for the nine months ended Q3 showed a loss of ¥315 million, compared with a loss of ¥1,900 million in the same period of the previous year. - FY2017MaterialisedAnnual report
「Overseas sales have remained high as a percentage of consolidated sales, at 84.2% in the fiscal year ended March 2016 and 82.6% in the fiscal year ended March 2017. The Company implements risk hedging through forward foreign exchange contracts and other measures, but the operating results and financial position of the Group are affected by foreign exchange fluctuations.」
Disclosed a high overseas exposure, with overseas sales accounting for 82.6% of sales, and stated that full-year overseas sales declined 3.0% due to the stronger yen. - FY2017-Q3MaterialisedAnnual report
「However, mainly due to the yen’s appreciation against other currencies, the Group’s overseas sales were ¥149,923 million, down 4.7% year on year, and accounted for 82.9% of sales, down 1.8 percentage points year on year.」
The impact of the stronger yen appeared as a factor behind the decline in overseas sales for the nine months ended Q3. Foreign exchange gains and losses in the condensed quarterly consolidated income statement also showed a loss of ¥1,900 million. - FY2017-Q2MaterialisedAnnual report
「However, mainly due to the yen’s appreciation against other currencies, the Group’s overseas sales were ¥97,793 million, down 4.6% year on year, and accounted for 82.3% of sales, down 1.9 percentage points year on year.」
The impact of the stronger yen again appeared as a factor behind lower overseas sales, and foreign exchange gains and losses showed a loss of ¥1,961 million. - FY2017-Q1MaterialisedAnnual report
「In Latin America, sales grew mainly in the hematology testing field on such factors as winning government projects in Mexico, measured in local-currency terms. However, the stronger yen also reduced sales, and sales in the Americas as a whole were ¥12,477 million, down 1.0% year on year.」
Foreign exchange risk materialized, with the stronger yen becoming a factor behind lower sales in the Americas. Foreign exchange gains and losses in the consolidated income statement also showed a loss of ¥1,597 million. - FY2016First statedAnnual report
「The Company implements risk hedging through forward foreign exchange contracts and other measures, but the operating results and financial position of the Group are affected by foreign exchange fluctuations.」
The Company identified exposure to foreign exchange fluctuations as a risk against a backdrop of the overseas sales ratio rising to 84.3%.